Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Primary Purpose
Left Ventricular Dysfunction
Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
PCI
Sponsored by
About this trial
This is an interventional basic science trial for Left Ventricular Dysfunction focused on measuring left ventricular dysfunction, myocardial infarction, left ventricular dysfunction (LVDF) after acute myocardial infarction
Eligibility Criteria
Inclusion Criteria:
- LVEF <40%
- PCI at latest 6 hours after infarction
- BMI >20 kg/m² and <30 kg/m²
Exclusion Criteria:
- PCI elder than 14 days
- relevant valvular disease
- left ventricular dysfunction caused by other reasons than ischemic cardiomyopathy
- history of stroke, chronic atrial fibrillation, multivessel disease, thromboembolic event
- scheduled for CABG
- DM Type 1 & extensive hypercholesterinemia
- pacemaker
- systemic disease
- Pregnancy
Sites / Locations
- Asklepios Klinik St. Georg, Departement of Cardiology
Outcomes
Primary Outcome Measures
Demonstration of safety and feasibility of BM-MNC treatment. Investigation of the suitability of endocardial left ventricular electromechanical mapping (LVEMM) with NOGA as endpoint for myocardial regeneration.
Secondary Outcome Measures
Collection of first evidence on the best type and time points for the determination of myocardial regeneration by NOGA and other parameters.
Full Information
NCT ID
NCT00938847
First Posted
July 13, 2009
Last Updated
July 13, 2009
Sponsor
Asklepios proresearch
Collaborators
Cordis Corporation
1. Study Identification
Unique Protocol Identification Number
NCT00938847
Brief Title
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Official Title
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration in Early Left Ventricular Dysfunction After Acute Myocardial Infarction And Successful Percutaneous Coronary Intervention
Study Type
Interventional
2. Study Status
Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
October 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Asklepios proresearch
Collaborators
Cordis Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Left Ventricular Dysfunction
Keywords
left ventricular dysfunction, myocardial infarction, left ventricular dysfunction (LVDF) after acute myocardial infarction
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
PCI
Intervention Description
Stent implantation after acute myocardial infarction
Primary Outcome Measure Information:
Title
Demonstration of safety and feasibility of BM-MNC treatment. Investigation of the suitability of endocardial left ventricular electromechanical mapping (LVEMM) with NOGA as endpoint for myocardial regeneration.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Collection of first evidence on the best type and time points for the determination of myocardial regeneration by NOGA and other parameters.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
LVEF <40%
PCI at latest 6 hours after infarction
BMI >20 kg/m² and <30 kg/m²
Exclusion Criteria:
PCI elder than 14 days
relevant valvular disease
left ventricular dysfunction caused by other reasons than ischemic cardiomyopathy
history of stroke, chronic atrial fibrillation, multivessel disease, thromboembolic event
scheduled for CABG
DM Type 1 & extensive hypercholesterinemia
pacemaker
systemic disease
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karl-Heinz Kuck, Prof. Dr. med.
Organizational Affiliation
Asklepios Klinik St. Georg, Departement of Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asklepios Klinik St. Georg, Departement of Cardiology
City
Hamburg
ZIP/Postal Code
20099
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
We'll reach out to this number within 24 hrs